Recursion Shares Fall as Investors Await Financial Results
The stock lagged major indexes in the latest session, while Zacks estimates point to higher quarterly revenue and a smaller per-share loss.
Makkler Newsroom · Sep 29, 01:24 AM · 1 min read
Recursion Pharmaceuticals, Inc. Class A RXRX
NASDAQHealth TechnologyUnited States
$3.19-0.15 (-4.35%)
Market closed· · USD · Data may be delayed
- Day's range
- 3.163.34
- 52-week range
- 2.775.24
Financial health
– / 5
Analyst view · 7 firms
Hold3 buy · 4 hold · 0 sell
Avg. target $6.82 (+114.0%)
Prices may be delayed and are for informational purposes only - not investment advice.